This filing is a procedural step clearing XpresTest's cap table for the pending sale. The key catalyst remains the stockholder vote on the Purchase Agreement — monitor for the definitive proxy statement and special meeting date. The activist support agreement suggests high likelihood of approval.
Price Chart
Executive Summary
XWELL's subsidiary XpresTest repurchased 279.5 restricted stock shares for ~$2.7M ($9,634.09/share) from executives and employees, simplifying XpresTest's capitalization ahead of the previously announced sale of XpresTest and XpresSpa to Express Wellness Group. The repurchases were accelerated with the buyer's consent and reduce the purchase price dollar-for-dollar as sale expenses. This is a procedural step advancing the pending sale, which is supported by an activist stockholder support agreement filed 29 days prior.
Key Facts
- XpresTest repurchased 279.5 restricted stock shares for ~$2.7M ($9,634.09/share) on October 8, 2026.
- Repurchases included shares from Chairman Bruce T. Bernstein ($1,030,847.61), CEO Ezra T. Ernst ($529,874.94), and CFO Ian Brown ($96,340.90).
- All unvested restricted shares became fully vested upon repurchase; no XpresTest RSAs remain outstanding.
- XWELL now owns 100% of XpresTest's outstanding capital stock.
- The repurchases were completed early with buyer consent to simplify capitalization ahead of the pending sale of XpresTest and XpresSpa to Express Wellness Group.
- The $2.7M paid will reduce the purchase price from Express Wellness Group dollar-for-dollar as sale expenses.
- A Support Agreement filed July 6, 2026 (SC 13D/A filed Sept 9, 2026) commits a holder of Series H Preferred Stock to vote in favor of the sale.
Financial Impact
~$2.7M cash outflow for share repurchases, which reduces the sale proceeds from Express Wellness Group by the same amount.
Risk Factors
- Sale could be delayed or terminated if stockholder approval is not obtained or conditions to closing are not satisfied.
- The $2.7M cash outflow reduces XWELL's cash position and the ultimate sale proceeds.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-114456 |
| Document: tm2621012d3_ex10-1.htm | 0001104659-26-114456 |
| Document: tm2621012d3_ex10-2.htm | 0001104659-26-114456 |
| Document: 0001104659-26-114456-index-headers.html | 0001104659-26-114456 |
| Document: 0001104659-26-114456-index.html | 0001104659-26-114456 |
| Document: 0001104659-26-114456.txt | 0001104659-26-114456 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | DEFA14A | $0.7000 | awaiting T+60 | — | $0.7400 (+5.71%) |
Oct 20, 2026 7d ago | 8-K | $0.6530 | awaiting T+60 | — | $0.7400 (−13.32%) |
Oct 7, 2026 20d ago | DEF 14A | $0.9200 | awaiting T+60 | — | $0.7400 (−19.57%) |
Oct 7, 2026 20d ago | 8-K | $0.9200 | awaiting T+60 | — | $0.7400 (−19.57%) |
Aug 5, 2026 11w ago | 8-K | $1.00 | awaiting T+60 | — | $0.7400 (−26.00%) |
Apr 16, 2026 27w ago | EFFECT | $1.04 $0.9399 | ▲ +9.63% | ▲ +16.67% | $0.7400 (+28.85%) |
Apr 1, 2026 29w ago | S-3 | $1.07 $1.04 | ▲ +2.80% | ▲ +16.96% | $0.7400 (+30.84%) |
Apr 1, 2026 29w ago | 8-K | $1.07 $1.04 | ▲ +2.80% | ▲ +16.96% | $0.7400 (+30.84%) |
Apr 1, 2026 29w ago | Press Release | $1.07 $1.04 | ▲ +2.80% | ▲ +16.96% | $0.7400 (+30.84%) |
Feb 25, 2026 34w ago | 8-K | $1.21 $1.46 | ▲ +20.66% | ▲ +13.71% | $0.7400 (−38.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers